Dr. Michael Roizen Longevity: How His Protocol Compares to Similar Public Figures

Who Is Dr. Michael Roizen and Why Does His Protocol Matter?

Dr. Michael Roizen is an anesthesiologist and internist who spent more than two decades as Chief Wellness Officer at Cleveland Clinic before moving to an emeritus role. He popularized the concept of "RealAge," a biological-age score calculated from lifestyle variables, through his 1999 book and the RealAge.com platform that followed. His reach is substantial: the RealAge test has reportedly been taken by more than 27 million people.

His Clinical Credentials

Roizen holds board certifications in both internal medicine and anesthesiology. His longevity interest is not purely commercial. He has co-authored peer-reviewed work on wellness program outcomes and has been affiliated with NIH-funded research at Cleveland Clinic. That institutional grounding separates him, at least partly, from wellness personalities who lack clinical training.

Why Compare Him to Peers?

The longevity-medicine space now includes several high-profile physician voices, each with a distinct evidence emphasis. Comparing Roizen to David Sinclair (Harvard), Peter Attia (Exercise and the older adult), and Rhonda Patrick (micronutrient biochemistry) allows readers to see where scientific consensus exists and where individual protocols diverge. Differences are often less about one person being wrong and more about which risk factor each clinician weights most heavily.

The RealAge Framework: Biological Age as a Clinical Tool

Roizen's foundational contribution is the idea that behavior shifts measurable biological age. The RealAge model assigns positive or negative age-years to specific habits. Not smoking at age 50 is worth roughly 8 years of biological youth in the model's scoring.

The Science Behind Biological Age Scoring

Biological age assessment has since matured considerably. Epigenetic clock research, particularly Steve Horvath's 2013 DNAm clock published in Genome Biology, showed that DNA methylation patterns predict mortality risk independently of chronological age [1]. A 2022 analysis in Nature Aging (N=11,052) confirmed that epigenetic age acceleration associates with all-cause mortality (hazard ratio 1.05 per year of acceleration, P<0.001) [2]. Roizen's RealAge model predates these molecular tools but anticipated the core insight: behavior changes biology.

How RealAge Compares to Modern Clocks

Modern biological-age tests used by Attia and Sinclair typically combine epigenetic methylation data with proteomics. Roizen's model is questionnaire-based, which makes it less precise but far more accessible. A 2018 review in Ageing Research Reviews noted that self-reported lifestyle composites still explain roughly 20 to 30 percent of variance in mortality outcomes, though molecular clocks explain more [3].

Dr. Roizen's Diet Protocol: What He Actually Eats

Roizen publicly follows a diet he describes as Mediterranean-adjacent: heavy on vegetables, legumes, whole grains, olive oil, and fish. He has specifically called out added sugar as the single highest-impact dietary target, citing its role in accelerating vascular aging.

Added Sugar and Vascular Age

His concern about sugar is well-supported. The PREDIMED trial (N=7,447) demonstrated that a Mediterranean diet supplemented with extra-virgin olive oil reduced major cardiovascular events by 30 percent compared with a low-fat control diet over approximately 4.8 years [4]. Roizen cites similar data when explaining why he avoids ultra-processed foods. He has stated in podcast interviews that he has not consumed a soft drink in more than 20 years.

Caloric Pattern

Roizen does not publicly endorse aggressive caloric restriction or prolonged fasting protocols, which distinguishes him from Attia (who has experimented with multi-day fasts) and Sinclair (who practices intermittent fasting daily). Roizen's stated preference is time-consistent eating without severe caloric deficit, a stance consistent with a 2022 CALERIE-2 follow-up published in Nature Aging showing that 25 percent caloric restriction for two years improved systemic inflammatory markers but produced musculoskeletal concerns in older participants [5].

Exercise: VO2 Max, Steps, and Strength

Roizen is vocal about exercise as the single most potent longevity intervention. He specifically names cardiorespiratory fitness as the variable that most reliably predicts healthy lifespan.

VO2 Max Emphasis

His emphasis on VO2 max aligns with Peter Attia's "Centenarian Decathlon" framework. A landmark study in JAMA (N=122,007) found that cardiorespiratory fitness was inversely associated with all-cause mortality across all fitness levels, with the largest survival benefit occurring between the "low" and "below average" fitness categories (hazard ratio 5.04, P<0.001) [6]. Roizen cites this category of evidence to argue that even modest fitness improvements in sedentary individuals yield outsized returns.

Resistance Training

Roizen recommends resistance training three times per week. This recommendation matches the American College of Sports Medicine position stand, which advises adults perform muscle-strengthening activities on two or more days per week [7]. Muscle mass preservation matters specifically for longevity because sarcopenia independently predicts mortality. A meta-analysis in BMJ Open (22 studies, N=68,566) found that low muscle mass was associated with a 23 percent higher all-cause mortality risk [8].

Steps and NEAT

His 10,000-steps daily target is more nuanced than the round number suggests. A 2022 JAMA Internal Medicine study (N=78,500 UK Biobank participants) found that 9,800 steps per day was the dose most associated with reduced dementia incidence, while 8,000 to 10,000 steps optimized cardiovascular outcomes [9]. Roizen's target sits within that evidence-supported range.

Supplements: What Dr. Roizen Takes and Why

This is where peer comparison becomes most informative. Roizen has publicly disclosed a supplement stack across multiple media appearances and in his books "AgeProof" (2017) and "The Great Age Reboot" (2023).

Omega-3 Fatty Acids

Roizen endorses fish oil at doses of 1 to 2 grams of EPA plus DHA daily. The REDUCE-IT trial (N=8,179) showed that 4 grams daily of icosapentaenoic acid (EPA, as icosapent ethyl) reduced major adverse cardiovascular events by 25 percent versus placebo in statin-treated patients with elevated triglycerides [10]. Roizen's cited dose is below the REDUCE-IT dose but sits within general cardiovascular prevention ranges supported by the American Heart Association [11].

Vitamin D3

He takes vitamin D3 and recommends blood 25-OH-D levels between 40 and 60 ng/mL. A 2022 VITAL trial sub-analysis (N=25,871) found that vitamin D3 supplementation (2,000 IU/day) reduced cancer mortality by 17 percent over 5.3 years but did not significantly reduce incident cancer or cardiovascular events [12]. The cancer-mortality finding is what Roizen tends to emphasize in public.

Resveratrol

Roizen has long advocated resveratrol, the polyphenol found in red wine and grape skins. David Sinclair also takes resveratrol (1,000 mg daily, per his public disclosures). The human evidence remains thin. A 2020 review in Nutrients concluded that resveratrol's bioavailability is low and that clinical trials have not consistently replicated the lifespan-extending effects seen in yeast and mouse models [13]. Both Roizen and Sinclair acknowledge this gap but argue the preclinical safety profile justifies use while larger trials continue.

CoQ10

Roizen recommends coenzyme Q10, particularly for patients on statins, given statins' known inhibition of the mevalonate pathway that also produces CoQ10. A 2018 meta-analysis in Mayo Clinic Proceedings (13 trials, N=1,120) found that CoQ10 supplementation significantly reduced statin-associated muscle symptoms (standardized mean difference -0.53, P<0.001) [14]. This is a narrower, better-supported use case than the broader anti-aging claims sometimes made for CoQ10.

NAD+ Precursors

In more recent interviews, Roizen has discussed NAD+ precursors, specifically nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN). NAD+ levels decline roughly 50 percent between ages 40 and 60 in human tissue studies [15]. Sinclair's lab has published extensively on NAD+ restoration in animal models, and Sinclair personally takes NMN at 1,000 mg daily. Roizen's public position is more cautious: he acknowledges the biology but notes that long-term human outcome data is still absent. A 2023 phase 2 trial in Nature Aging (N=30) showed NMN supplementation raised blood NAD+ metabolites by 38 percent but did not change insulin sensitivity over 10 weeks [16].

Pharmaceutical Interventions: Where Roizen Differs Most From Peers

This is the sharpest point of divergence between Roizen and the other longevity physicians discussed here. Roizen is considerably more conservative about off-label pharmaceutical use than Attia or Sinclair.

Statins and Low-Dose Aspirin

Roizen has publicly stated he takes a low-dose statin and, until 2019 guideline updates, endorsed low-dose aspirin for primary prevention in select patients. The 2018 USPSTF recommendation on aspirin moved against routine primary prevention use citing bleeding risk, a position the FDA reinforced in 2021 [17]. Roizen updated his public guidance accordingly, which demonstrates clinical responsiveness to new data.

Metformin

Sinclair takes metformin 1,000 mg/day off-label for longevity. Attia has reversed his earlier metformin stance after the TAME (Targeting Aging with Metformin) trial interim signals suggested metformin might blunt exercise adaptations. A 2022 study in Aging Cell (N=53) found that metformin attenuated the mitochondrial and insulin-sensitivity benefits of aerobic exercise in older adults [18]. Roizen has not publicly stated he takes metformin for longevity, though he has discussed its mechanism favorably in educational content.

Rapamycin

Attia is perhaps the most prominent physician to disclose personal rapamycin use (intermittent low-dose, approximately 6 mg weekly). Roizen has not publicly disclosed rapamycin use and has been measured in his commentary, noting that mTOR inhibition's effect on immune function in healthy adults warrants more study before routine adoption.

Sleep and Stress: The Under-Discussed Variables

Roizen consistently places sleep and stress reduction in his top-five longevity levers, a stance backed by strong epidemiological data.

Sleep Duration and Mortality

A 2021 meta-analysis in Sleep Medicine Reviews (74 studies, N=3,340,684) found that both short sleep (<6 hours) and long sleep (>9 hours) were associated with significantly higher all-cause mortality, with the lowest risk at 7 to 8 hours nightly [19]. Roizen publicly targets 7.5 hours and has discussed sleep tracking via wearables.

Chronic Stress and Biological Aging

His stress-reduction emphasis aligns with research showing that psychological stress accelerates telomere attrition. A seminal study by Epel and colleagues in PNAS (2004, N=58) found that chronically stressed caregivers had telomeres equivalent to roughly 10 additional years of aging compared with low-stress controls [20].

How Roizen Compares to Sinclair, Attia, and Patrick: A Direct Assessment

Each of these four figures draws on overlapping evidence but weights it differently.

David Sinclair

Sinclair's protocol is more aggressively pharmaceutical: NMN 1,000 mg, resveratrol 1,000 mg, metformin 1,000 mg, low-dose rapamycin intermittently, and a statin. He practices intermittent fasting and tracks biological age via epigenetic tests quarterly. His public communications lean heavily on his own lab's animal data, which some clinicians view as premature extrapolation to humans.

Peter Attia

Attia prioritizes VO2 max and muscle mass above almost everything else. His supplement stack is comparatively minimal; he has been vocal that most supplements lack adequate human outcome data. He does use low-dose rapamycin and, previously, metformin. His "Medicine 3.0" framework emphasizes individualized risk stratification over population-level recommendations, which means his protocol varies by patient rather than following a single public template.

Rhonda Patrick

Patrick's focus sits on micronutrient sufficiency, particularly vitamin D, magnesium, and omega-3s, plus heat and cold hormesis (sauna and cold plunge). Her protocol has the greatest overlap with Roizen's dietary and supplementation approach. She does not publicly discuss pharmaceutical longevity agents.

Where Roizen Sits

Roizen occupies a middle position: more evidence-conservative than Sinclair, more supplement-positive than Attia, and more pharmaceutically engaged than Patrick. His institutional affiliation with Cleveland Clinic has historically anchored him to FDA-approved interventions or supplements with at least plausible human mechanistic data. "The data on lifestyle changes show you can reduce your biological age by 25 to 30 years," Roizen stated in a 2023 interview with Cleveland Clinic Health Essentials, "and the interventions are not complicated."

The Cleveland Clinic Wellness Program: Institutional Context

Roizen did not just theorize about longevity. He built one of the largest employer wellness programs in U.S. Healthcare while at Cleveland Clinic. The program, which enrolled more than 100,000 staff and dependents, tracked biometric improvements over multiple years.

Outcomes Data

Internal Cleveland Clinic data, cited in Roizen's 2023 book, reported that participants who engaged with the wellness program for five or more years showed a mean 1.7-year reduction in RealAge score compared with non-participants. Independent validation of these proprietary figures is limited, which is a fair methodological criticism. External evidence for comprehensive workplace wellness programs is mixed. A 2019 JAMA study (N=32,974) found that a large worksite wellness program improved self-reported health behaviors but did not significantly change clinical measures like BMI or blood pressure at 18 months [21].

Safety Profile and Potential Risks of Roizen's Protocol

For most adults, Roizen's protocol is low-risk. The diet is consistent with AHA and ADA guidelines. Exercise recommendations align with CDC physical activity guidelines (150 minutes of moderate aerobic activity weekly for adults) [22].

Supplement Interactions

High-dose fish oil (above 3 grams EPA+DHA daily) may increase bleeding risk, particularly in patients on anticoagulants. The FDA issued a qualified health claim for omega-3s but has not approved high-dose fish oil as a general preventive supplement without a triglyceride indication [23]. Roizen's cited doses stay below the threshold where this risk becomes clinically significant for most patients.

Who Should Be Cautious

Patients on warfarin, those with bleeding disorders, or individuals with liver disease should consult a physician before adding CoQ10 or high-dose omega-3s. Vitamin D toxicity occurs at sustained serum levels above 150 ng/mL, well above Roizen's 40 to 60 ng/mL target. The 2011 Institute of Medicine (now National Academy of Medicine) review set the tolerable upper intake for vitamin D at 4,000 IU/day for adults, above which adverse effects become measurable [24].